A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Clinical trial NCT07608354 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07608354
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Start date: 2026-06-11
Primary completion: 2029-02-06
Enrollment: 326

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.